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Abstract
Lung cancer as a second primary malignancy (lung‐2) is increasingly common, but 
its prognosis is poorly understood. This study aims to examine the overall and can-
cer‐specific survival of patients diagnosed with lung‐2 compared to lung‐1. Primary 
lung cancer patients diagnosed from 1988 to 2014 in the Surveillance, Epidemiology, 
and End Results (SEER) program were included. Lung‐2 was identified in patients 
with a previous diagnosis of nonlung primary malignancy in SEER. Hazard ratios 
(HRs) of overall and lung cancer‐specific mortality were estimated among patients 
with lung‐2 compared to lung‐1, adjusting for age and calendar period at diagnosis, 
sex, race, socioeconomic status, tumor stage, histology, tumor grade, and treatment. 
A total of 679 541 and 85 758 patients were identified as lung‐1 and lung‐2, respec-
tively. Compared to lung‐1, patients with lung‐2 were more likely to be diagnosed at 
localized stage, with smaller primary tumor, and treated with surgery. Lung‐2 pa-
tients were at lower risk of lung cancer‐specific mortality in the first 5 years (HR, 
0.77; 95% CI, 0.76‐0.78 at <1 year; HR, 0.87; 95% CI, 0.86‐0.89 from 1 to <5 years) 
but at higher risk thereafter (HR, 1.32; 95% CI, 1.27‐1.37 from 5 to 10 years), inde-
pendent of tumor characteristics and cancer treatment. Similar pattern was found for 
overall mortality, although the survival benefit was restricted to the first year after 
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1 |  INTRODUCTION
As the survival of cancer patients improves, second primary 
malignancy has been increasingly diagnosed among cancer 
survivors.1 Many cancer survivors are at increased risk of de-
veloping second primary lung cancer (lung‐2), due to shared 
hazardous lifestyles, cancer treatment, and intrinsic genetic fac-
tors of the first primary ones.2,3 However, it is largely unknown 
whether lung‐2 itself has a different aggressiveness compared 
to lung cancer as the first primary malignancy (lung‐1).
Clinical decision‐making for patients presenting with 
lung‐2 sometimes can be challenging because of the limited 
and conflicting information on prognosis. A study of Hodgkin 
lymphoma patients who developed lung‐2 showed inferior 
overall survival of lung‐2 compared to lung‐1,4 whereas the 
overall survival of lung‐2 among breast cancer survivors was 
not worse compared to lung‐1.5 The reduced overall survival 
(if any) is, however, not surprising, given the non‐negligible 
mortality contribution of the first primary cancer, and does 
not necessarily indicate more aggressive behavior of lung‐2.
To better capture the prognosis of lung‐2, lung cancer‐
specific mortality, rather than overall survival, is indeed 
the optimal measure. Yet, such evidence on lung‐2 is cur-
rently lacking. We therefore utilized the well‐established 
Surveillance, Epidemiology, and End Results (SEER) data-
base to examine the risks of lung cancer‐specific and overall 
mortality among patients with lung‐2 compared to lung‐1, 
and whether tumor, clinical, and demographic factors could 
potentially modify such risks.
2 |  MATERIALS AND METHODS
2.1 | Study population
Based on National Cancer Institute's SEER program, we 
conducted a population‐based cohort study of patients with 
primary lung cancer diagnosed between January 1, 1988 and 
December 31, 2014 in US. SEER has collected information 
on demographic, tumor and clinical characteristics, and fol-
low‐up from nine registries since 1997 (covering about 9.4% 
of the US population) and expanded to 13 registries in 1992 
(about 13.4% of the US population). We identified 989 150 
patients with primary lung cancer confirmed by pathologi-
cal diagnosis. The following patients were further excluded: 
diagnosed from autopsy (N = 20 602), younger than 18‐year‐
old (N = 188), with no birth year (N = 21), and without ac-
curate follow‐up (N = 101 814).
2.2 | Ascertainment of first and second 
primary lung cancer
SEER has stringent criteria to define multiple primary neo-
plasms. Because pathological diagnosis is required for inclu-
sion, it is less likely that lung‐2 identified in SEER constitute 
metastases from the first primary malignancy unless the first 
primary is lung cancer. Per SEER rules, an uncertain case is 
considered as a single primary unless proven as a new primary.6
Among the remaining 866 525 patients, 186 984 were re-
corded as not their first malignancy. By linking to the pre-
vious malignancy diagnoses in SEER, we further excluded 
patients with lung cancer as the third or above primary ma-
lignancy (N = 18 152), and patients with no information on 
previous malignancy diagnosis (N = 63 484). Because of the 
uncertainty of separating a lung‐2 from intrapulmonary me-
tastases of lung‐1 and the difficulty to determine death from 
lung‐1 or lung‐2 patients with a prior history of lung cancer 
were also excluded (N = 19 590). Thus, lung‐2 in this anal-
ysis represents primary lung cancer as a second malignancy 
after a prior nonlung malignancy. Finally, we identified 
765 299 patients with primary lung cancer, including 85 758 
lung‐2 and 679 541 lung‐1.
2.3 | Ascertainment of mortality
We studied lung cancer‐specific mortality as primary out-
come and overall mortality as secondary outcome. All pa-
tients were followed from cancer diagnosis until December 
31, 2014 or death, whichever came first, by linking registries 
through health care institutions or by directly contacting pa-
tients. The cause of death is derived from death certificate 
with algorithms to identify a single, disease‐specific cause. 
The algorithm considers tumor sequence, site of the cancer 
diagnosis, and comorbidities.7
2.4 | Statistical analysis
First, we described the demographic, tumor, and clinical 
characteristics between patients with lung‐1 and lung‐2. The 
diagnosis. Patients diagnosed with lung‐2 face a favorable lung cancer‐specific sur-
vival within the early period after diagnosis. A conservative approach to manage 
lung‐2 solely based on malignancy history is not supported.
K E Y W O R D S
cohort study, lung cancer, mortality, prognosis, second primary
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association of lung‐2 with tumor and clinical characteristics 
was analyzed by using binary or multinomial logistic regres-
sion. Demographic characteristics were adjusted for in the 
analysis of tumor characteristics, while tumor features were 
additionally controlled for in the analysis of clinical charac-
teristics. Education level and cost of living were obtained at 
county level with data annexed to SEER.
We plotted the cumulative mortality rates by causes of 
death among patients with lung‐1 and lung‐2 from diagno-
sis to 10 years afterwards. Because the proportional haz-
ards assumption was violated, we derived the hazard ratios 
(HRs) and 95% confidence intervals (CIs) of overall and 
lung cancer‐specific mortality among lung‐2 from a flexi-
ble parametric survival model,8 which allows HRs to change 
over time. To address the concern of misclassification of 
causes of death (eg, deaths due to lung‐2 attributed to the 
first primary malignancy or vice versa), we additionally an-
alyzed the association with any cancer‐specific mortality.
In the aforementioned analyses, we always adjusted for 
demographic characteristics in a first model (model A) and 
additionally controlled for tumor and clinical characteris-
tics—as potential mediators (eg, patients with lung‐2 are 
more likely to be diagnosed at earlier stage and subsequently 
have better survival)—in a second model (model B). Age was 
used as a continuous variable, while other factors were cate-
gorized. Our emphasis was though on reporting associations 
independent of tumor and clinical characteristics, thus we 
only applied model B on the analyses below.
Given the heterogeneous HRs over time, the subsequent 
analyses on factors of first malignancy and lung cancer 
were separately performed within different follow‐up pe-
riods (0 to <1 year, 1 to <5 years, and 5 to 10 years after 
diagnosis), using Cox proportional hazards models. To ad-
dress the concern of higher possibility of dying from first 
primary malignancy among patients with lung‐2, we es-
timated the HR of lung cancer‐specific mortality using a 
competing risk model.9
We performed all analyses in STATA 14.2 (StataCorp 
LP). P < 0.05 indicated statistical significance. The study 
was approved by the Biomedical Research Ethics Committee 
at West China Hospital.
3 |  RESULTS
3.1 | Patients and clinical characteristics
A total of 679 541 and 85 758 patients had lung‐1 and 
lung‐2, respectively, with a median follow‐up of 0.6 year 
(0‐26.9 years). Lung‐2 accounted for 8.8% of the total new 
cases in 1988‐1992 and 14.5% in 2011‐2014 (Figure S1). 
Compared to lung‐1, patients with lung‐2 were older and 
diagnosed more recently (Table S1), more likely to be 
diagnosed at localized stage, with smaller tumor size, 
squamous, and well‐and‐moderately differentiated tu-
mors (Table S2). Lung‐2 patients were more likely to un-
dergo surgery, but less likely to receive radiation therapy 
(Table S2). Among lung‐2 patients, the median time from 
the first malignancy to lung‐2 diagnosis was 4.8 years. The 
most common three sites of first malignancy were prostate, 
breast, and colon and rectum (Figure S2).
F I G U R E  1  Cumulative mortality rates by causes of death among patients with first and second primary lung cancers from cancer diagnosis 
to 10 years afterwards: a population‐based cohort study in US, 1988‐2014
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3.2 | Mortality risk of lung‐2 relative to 
lung‐1
A total of 551 134 (81.1%) and 69 714 (81.3%) lung‐1 and 
lung‐2 patients died during follow‐up. Compared to lung‐1, 
patients with lung‐2 had lower cumulative mortality rate 
due to lung cancer, but higher cumulative mortality rate 
due to other cancers, from diagnosis to 10 years afterwards 
(Figure 1). The cumulative mortality rate of all causes was 
lower in lung‐2 until almost 7 years after diagnosis.
In the first 1 and 2 years after diagnosis, patients with 
lung‐2 had decreased risk of overall mortality when adjusting 
F I G U R E  2  Hazards ratios (HRs) of overall and lung cancer‐specific mortality among patients with second primary lung cancer from cancer 
diagnosis to 10 years afterwards, compared to patients with first primary lung cancer: a population‐based cohort study in US, 1988‐2014. HRs were 
estimated from flexible parametric survival models, allowing the effect of second primary lung cancer to vary over time. A spline with 5 df (four 
intermediate knots and two knots at each boundary, placed at quintiles of distribution of events) was used for the baseline rate, while 3 df was used 
for the time‐varying effect. HRs in model A were adjusted for age and calendar period at diagnosis, sex, race, cohabitation status, and percentile of 
high‐school education and cost of living in county of residence. HRs in model B were additionally adjusted for tumor stage, histology, tumor grade, 
and treatment modalities
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for tumor and clinical characteristics (Figure 2). However, the 
risk of overall mortality increased thereafter through 10 years 
after diagnosis of lung cancer. Regarding lung cancer‐specific 
mortality, lung‐2 patients had consistently decreased risk until 
10 years after diagnosis. However, when adjusting for tumor 
and clinical characteristics, the risk of lung cancer‐specific mor-
tality started to increase from 5 years after diagnosis. Of note, 
even if all deaths due to other cancers were attributed to lung 
cancer, lung‐2 patients still had lower risk of any cancer‐spe-
cific mortality during the first year after diagnosis (Figure S3).
To provide practical estimates, we also calculated the 
HRs over time by separating follow‐up into three periods (0 
to <1 year, 1 to <5 years, and 5 to 10 years after diagnosis) 
in Table 1, which largely corroborates the temporal pattern in 
Figure 2. The association with lung cancer‐specific mortality 
was further confirmed by considering competing risks, such 
as dying from cancers other than lung and noncancer causes 
(Table S3).
3.3 | Factors of first malignancy that 
modified the risk of mortality
Regarding lung cancer‐specific mortality, the same tem-
poral pattern was found for all lung‐2 patients, except for 
patients with a history of breast and uterine cancers, who 
had noninferior mortality, but the monotonic increase of 
HR over time is similar to other cancers (Table 2). The 
risk reduction of lung cancer‐specific mortality during 
first 5 years, particularly within first year, after diagnosis 
was greater among lung‐2 patients with regional or distant 
stage as first malignancy. The earlier lung‐2 patients were 
diagnosed from the first malignancy, the lower the lung 
cancer‐specific mortality.
In terms of overall mortality, the same temporal pattern was 
found for all lung‐2 patients, except for patients with previous 
hematopoietic and lymphatic malignancies, who had increased 
risk of overall mortality at all time points (Table 3). More ad-
vanced stage of the first malignancy was associated with poorer 
overall mortality throughout follow‐up. Time from first primary 
did not clearly modulate the association with overall mortality.
3.4 | Factors of lung cancer that 
modified the risk of mortality
When comparing lung‐2 to lung‐1, smaller HRs of lung can-
cer‐specific mortality were found from diagnosis to 10 years 
afterwards among women and patients not receiving surgery 
(Table S4). Men are consistently associated with worse lung 
cancer‐specific mortality. Larger HRs of overall mortality were 
observed among patients with localized stage and those who 
received surgery (Table S5). Other factors of lung‐2 including 
race did not clearly modify the association with mortality risks.
4 |  DISCUSSION
Leveraging a large population‐based cohort, to the best of 
our knowledge, this is the first study to comprehensively 
investigate the prognosis of lung cancer as the second pri-
mary malignancy (lung‐2) revealing a distinct, time‐varying 
disease course. Our findings suggest that lung cancer‐spe-
cific survival of lung‐2 is not necessarily inferior to lung‐1, 
T A B L E  1  Hazard ratios (HRs) of overall and lung cancer‐specific mortality among patients with second primary lung cancer, by time since 
diagnosis, compared to patients with first primary lung cancer: a population‐based cohort study in US, 1988‐2014
 No. of patients
From 0 to < 1 y after 
diagnosis
From 1 to < 5 y after 
diagnosis












679 541 383 208 (99.9) 1.00 135 513 (29.3) 1.00 16 821 (9.8) 1.00
Second primary 
lung cancer
85 758 44 288 (84.1) 0.91 
(0.91‐0.92)
20 073 (29.4) 1.10 
(1.08‐1.12)





679 541 325 633 (84.9) 1.00 111 348 (24.1) 1.00 8147 (4.7) 1.00
Second primary 
lung cancer
85 758 31 247 (59.3) 0.77 
(0.76‐0.78)
12 485 (18.3) 0.87 
(0.86‐0.89)
1158 (5.4) 1.10 
(1.03‐1.17)
Note: Abbreviations: CI, confidence interval; IR, incidence rate per 100 person‐years; N, number of deaths.
aHRs were adjusted for age and calendar period at diagnosis, sex, race, cohabitation status, percentile of cost of living and high‐school education in county of 
residence, tumor stage, histology, tumor grade, surgery, radiation therapy, and chemotherapy. 
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particularly during the first 5 years after diagnosis. Such as-
sociation is to some extent explained by, yet independent of, 
a range of important prognostic factors, including tumor and 
clinical characteristics. The reduced risk of overall mortality 
in lung‐2 is restricted to the first year after diagnosis, whereas 
the long‐term overall survival is in fact compromised. As 
lung‐2 is increasingly common in recent years, our results 
may provide timely guidance for clinical evaluations and 
decisions.
Our findings do not suggest that lung‐2 generally is 
more aggressive than lung‐1, although some evidence in-
dicated that second primary cancer may be biologically 
different from the first one. A study of lung and breast 
cancer in irradiated Hodgkin lymphoma survivors showed 
that they had higher microsatellite alterations than their 
de novo counterpart.10 Breast cancer in this setting also 
demonstrated higher proliferative index.11 In our study, 
we showed that patients with lung‐2 had decreased risk 
of lung cancer‐specific mortality, particularly during the 
first 5 years after diagnosis and in patients with a previous 
breast or uterine cancer. This is in line with an earlier report 
that lung‐2 that developed in breast cancer survivors had 
better lung cancer‐specific survival.5 Studies showed that 
the risk of second lung cancer arises mostly 10 years after 
the first primary cancer.12-16 Of note, the survival benefits 
are somewhat attenuated among lung‐2 diagnosed 10 years 
after the first malignancy. Because the second primary at-
tributed to treatment of the first primary is not common 
(6% among breast cancer survivors),17 it is, however, less 
likely that the presumable biological difference of lung‐2 
due to treatment may substantially drive the entire associa-
tion toward unfavorable survival (if any).
Given the lower lung cancer‐specific mortality in the first 
5 years after diagnosis, our study argues against conservative 
T A B L E  2  Hazard ratios (HRs) of lung cancer‐specific mortality among patients with second primary lung cancer, by characteristics of the 
first malignancy, compared to patients with first primary lung cancer: a population‐based cohort study in US, 1988‐2014
 
No. (%) of 
patients
From 0 to < 1 y after diagnosis From 1 to < 5 y after diagnosis
From 5 to 10 y of follow‐up after 
diagnosis
N (IR) HR (95% CI)a N (IR) HR (95% CI)a N (IR) HR (95% CI)a 
By sites of first malignancy
Prostate 20 661 (24.1) 8907 (75.0) 0.79 (0.78‐0.81) 3092 (22.5) 0.90 (0.87‐0.93) 255 (6.3) 1.11 (0.98‐1.27)
Breast 13 678 (15.9) 3989 (42.8) 0.68 (0.66‐0.70) 1942 (13.6) 0.75 (0.72‐0.79) 222 (4.4) 0.96 (0.84‐1.09)
Colon and 
rectum
9741 (11.4) 3412 (54.8) 0.72 (0.70‐0.75) 1441 (17.0) 0.83 (0.79‐0.87) 142 (5.2) 1.00 (0.85‐1.18)
Urinary 
bladder
8486 (9.9) 3592 (71.6) 0.83 (0.80‐0.86) 1318 (22.5) 0.95 (0.90‐1.00) 123 (7.2) 1.36 (1.14‐1.63)
Blood 6597 (7.7) 2343 (59.9) 0.84 (0.81‐0.88) 900 (18.6) 1.00 (0.93‐1.07) 68 (5.3) 1.13 (0.89‐1.43)
Larynx 3779 (4.4) 1340 (56.4) 0.80 (0.76‐0.84) 560 (20.6) 0.96 (0.88‐1.04) 50 (6.2) 1.38 (1.05‐1.83)
Skin 3108 (3.6) 1200 (61.8) 0.79 (0.74‐0.83) 482 (17.7) 0.89 (0.82‐0.98) 51 (5.4) 1.25 (0.95‐1.65)
Kidney 2565 (3.0) 803 (47.5) 0.69 (0.64‐0.74) 343 (14.2) 0.75 (0.68‐0.84) 35 (4.6) 1.06 (0.76‐1.48)
Uterus 2292 (2.7) 799 (54.3) 0.75 (0.70‐0.80) 348 (16.8) 0.85 (0.76‐0.94) 38 (4.9) 0.97 (0.70‐1.33)
Thyroid 1231 (1.4) 360 (43.2) 0.67 (0.60‐0.74) 191 (14.9) 0.79 (0.68‐0.91) 20 (4.6) 1.00 (0.65‐1.56)
Others 13 620 (15.9) 4502 (53.9) 0.78 (0.76‐0.80) 1868 (18.9) 0.92 (0.88‐0.96) 154 (5.4) 1.20 (1.02‐1.41)
By tumor stage of first malignancy
Localized 50 465 (58.8) 19 277 (61.3) 0.80 (0.79‐0.81) 7776 (18.8) 0.88 (0.86‐0.90) 752 (5.7) 1.14 (1.05‐1.23)
Regional 15 626 (18.2) 4801 (47.7) 0.69 (0.67‐0.71) 2121 (15.8) 0.82 (0.78‐0.85) 190 (4.4) 0.97 (0.84‐1.12)
Distant 5653 (6.6) 1802 (56.5) 0.69 (0.66‐0.73) 621 (18.7) 0.86 (0.80‐0.93) 35 (4.6) 1.00 (0.71‐1.39)
Unstaged 14 014 (16.3) 5367 (64.6) 0.78 (0.76‐0.81) 1967 (19.6) 0.90 (0.86‐0.94) 181 (6.0) 1.15 (0.99‐1.34)
By time elapsed from first malignancy
0 to < 2 y 25 925 (30.2) 7334 (43.0) 0.63 (0.62‐0.65) 3613 (15.0) 0.78 (0.76‐0.81) 402 (4.9) 1.07 (0.97‐1.19)
2 to < 5 y 21 484 (25.1) 7953 (58.9) 0.78 (0.76‐0.80) 3253 (18.7) 0.88 (0.85‐0.91) 305 (5.4) 1.09 (0.97‐1.22)
5 to < 10 y 21 268 (24.8) 8621 (67.9) 0.84 (0.83‐0.86) 3174 (20.4) 0.93 (0.90‐0.96) 249 (5.7) 1.11 (0.98‐1.26)
≥10 y 17 081 (19.9) 7339 (75.2) 0.88 (0.86‐0.90) 2445 (22.0) 0.94 (0.90‐0.98) 202 (6.2) 1.18 (1.03‐1.36)
Note:. Abbreviations: CI, confidence interval; IR, incidence rate per 100 person‐years; N, number of deaths; y, years.
aHR was adjusted for were adjusted for age and calendar period at diagnosis, sex, race, cohabitation status, percentile of cost of living and high‐school education in 
county of residence, tumor stage, histology, tumor grade, surgery, radiation therapy, and chemotherapy. 
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management of lung‐2 simply because it is a second primary 
malignancy. One might speculate that patients with lung‐2 
would receive more conservative treatment. As a matter of 
fact, our study showed that lung‐2 patients are managed more 
aggressively in the real world—they are 20% more likely to 
receive surgical treatment with adjustment for tumor char-
acteristics. Because the median time to lung‐2 diagnosis is 
about 5 years after the first primary, it is plausible that many 
of lung‐2 are diagnosed during the routine surveillance of the 
first malignancy (ie, better access to health care) and are de-
tected by “screening.” For instance, we observed the greatest 
risk reduction of lung cancer‐specific mortality among pa-
tients with lung‐2 diagnosed within 2 years after first malig-
nancy. It is further supported by our findings that lung‐2 is 
more likely to be diagnosed at early stage and with a smaller 
size. However, the associations remain robust after fine ad-
justment for tumor characteristics and cancer treatment, 
suggesting that the favorable cancer‐specific survival among 
lung‐2 is independent of above prognosticators.
The time‐varying disease course of patients with lung‐2 
has not been revealed previously. The favorable overall sur-
vival in lung‐2 was restricted to the first year after diagnosis. 
In the long run, patients with lung‐2 had worse overall sur-
vival. It is plausible that the progression of first malignancy 
contributed to the increased risks of overall mortality from 
1 year after diagnosis onward. It is supported by the fact that 
highest increased risk of overall mortality, but not lung can-
cer‐specific mortality among lung‐2 patients with first malig-
nancy diagnosed at distant stage.
Previous studies that investigated lung‐2 in cancer survi-
vors of specific cancer sites have yielded seemingly incon-
sistent results. Overall survival of non‐small cell lung cancer 
in Hodgkin lymphoma and chronic lymphocytic leukemia 
survivors has been reported to be worse than their de novo 
T A B L E  3  Hazard ratios (HRs) of overall mortality among patients with second primary lung cancer, by characteristics of the first 
malignancy, compared to patients with first primary lung cancer: a population‐based cohort study in US
 
No. (%) of 
patients
From 0 to < 1 y after diagnosis From 1 to < 5y after diagnosis
From 5 to 10 y of follow‐up after 
diagnosis
N (IR) HR (95% CI)a N (IR) HR (95% CI)a N (IR) HR (95% CI)a 
By sites of first malignancy
Prostate 20 661 (24.1) 11 830 (99.6) 0.88 (0.86‐0.90) 4509 (32.8) 1.02 (0.99‐1.05) 693 (17.2) 1.26 (1.17‐1.36)
Breast 13 678 (15.9) 5800 (62.2) 0.83 (0.81‐0.85) 3340 (23.4) 1.03 (0.99‐1.06) 620 (12.2) 1.28 (1.18‐1.39)
Colon and 
rectum
9741 (11.4) 4849 (77.9) 0.85 (0.83‐0.88) 2496 (29.5) 1.10 (1.06‐1.15) 417 (15.3) 1.27 (1.16‐1.40)
Urinary 
bladder
8486 (9.9) 4763 (94.9) 0.92 (0.89‐0.95) 1930 (32.9) 1.09 (1.04‐1.14) 287 (16.8) 1.32 (1.17‐1.48)
Blood 6597 (7.7) 3532 (90.3) 1.06 (1.03‐1.10) 1492 (30.9) 1.28 (1.22‐1.35) 224 (17.4) 1.66 (1.46‐1.90)
Larynx 3779 (4.4) 2014 (84.8) 1.01 (0.96‐1.05) 1007 (37.0) 1.35 (1.26‐1.43) 149 (18.5) 1.72 (1.46‐2.02)
Skin 3108 (3.6) 1547 (79.7) 0.85 (0.81‐0.90) 681 (25.0) 1.00 (0.92‐1.07) 103 (10.9) 1.09 (0.90‐1.32)
Kidney 2565 (3.0) 1159 (68.6) 0.83 (0.78‐0.88) 582 (24.1) 0.99 (0.91‐1.08) 102 (13.4) 1.35 (1.11‐1.64)
Uterus 2292 (2.7) 1102 (74.9) 0.87 (0.82‐0.92) 526 (25.4) 1.01 (0.93‐1.10) 91 (11.8) 1.10 (0.89‐1.35)
Thyroid 1231 (1.4) 492 (59.0) 0.77 (0.71‐0.84) 262 (20.4) 0.88 (0.78‐0.99) 41 (9.4) 1.03 (0.76‐1.40)
Others 13 620 (15.9) 7200 (86.2) 1.05 (1.02‐1.07) 3248 (32.9) 1.27 (1.22‐1.31) 406 (14.3) 1.47 (1.33‐1.62)
By tumor stage of first malignancy
Localized 50 465 (58.8) 25 576 (81.3) 0.89 (0.88‐0.90) 11 576 (27.9) 1.03 (1.01‐1.05) 1868 (14.1) 1.25 (1.19‐1.31)
Regional 15 626 (18.2) 7629 (75.8) 0.91 (0.89‐0.93) 3975 (29.6) 1.20 (1.16‐1.24) 585 (13.5) 1.37 (1.26‐1.48)
Distant 5653 (6.6) 3278 (102.8) 1.05 (1.02‐1.09) 1259 (38.0) 1.38 (1.31‐1.46) 139 (18.3) 1.87 (1.58‐2.21)
Unstaged 14 014 (16.3) 7805 (93.9) 0.95 (0.93‐0.97) 3263 (32.5) 1.15 (1.11‐1.19) 541 (17.8) 1.44 (1.32‐1.57)
By time elapsed from first malignancy
0 to < 2 y 25 925 (30.2) 12 295 (72.0) 0.88 (0.86‐0.90) 6681 (27.7) 1.13 (1.10‐1.16) 1132 (13.8) 1.35 (1.27‐1.43)
2 to < 5 y 21 484 (25.1) 11 107 (82.3) 0.91 (0.89‐0.93) 5201 (29.8) 1.11 (1.08‐1.14) 822 (14.7) 1.31 (1.22‐1.40)
5 to < 10 y 21 268 (24.8) 11 462 (90.3) 0.94 (0.92‐0.96) 4718 (30.3) 1.09 (1.06‐1.12) 678 (15.7) 1.34 (1.24‐1.45)
≥10 y 17 081 (19.9) 9424 (96.6) 0.94 (0.92‐0.96) 3473 (31.3) 1.05 (1.02‐1.09) 501 (15.4) 1.27 (1.16‐1.39)
Note:. Abbreviations: CI, confidence interval; IR, incidence rate per 100 person‐years; N, number of deaths; y, years.
aHR was adjusted for were adjusted for age and calendar period at diagnosis, sex, race, cohabitation status, percentile of cost of living and high‐school education in 
county of residence, tumor stage, histology, tumor grade, surgery, radiation therapy, and chemotherapy. 
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counterparts,4,18 but not in breast cancer survivors.5 These 
seemingly contrary findings to ours are explained by our ap-
proach of examining sites of first malignancies individually 
and disentangling temporal patterns. Lung‐2 patients with 
hematopoietic and lymphatic malignancy as the first primary 
stood out as the only primary malignancies that had worse 
overall survival during follow‐up. For the remaining first ma-
lignancies, including breast cancer, lung‐2 patients did not 
have elevated risk of overall mortality within the first year of 
diagnosis. Our findings suggest that factors other than lung‐2, 
such as the first primary cancer may play a significant role in 
the overall mortality of lung‐2 patients.
The major strength of our study is the large‐scale popula-
tion‐based prospective cohort of patients with primary lung 
cancer, which assures minimal common biases including se-
lection and surveillance biases. Our comprehensive analyses 
on the temporal pattern of mortality risk and characteristics 
of first malignancy helped explain conflicting results in pre-
vious literatures. Our study has several limitations. First, 
findings could be in part explained by competing risk, yet 
reassuringly, analysis with competing risk model resulted in 
even stronger associations. Second, the cause of death may 
be recorded incorrectly, but a validation study showed fairly 
good agreement rate for lung cancer‐specific survival.19 
Also, our additional analysis on any cancer‐specific mortal-
ity showed that even attributing all deaths of other cancers to 
lung cancer, lung‐2 patients remain at a reduced risk of any 
cancer‐specific mortality during the first year after diagno-
sis. Third, a few factors that associated with survival are not 
recorded, including tobacco use and comorbidities, although 
such factors are more influential to overall, instead of cancer‐
specific, mortality. Finally, our study did not include lung‐2 
with lung cancer as its first primary, due to the challenge of 
disentangling lung‐2 from pulmonary metastases.
In conclusion, patients with second primary lung cancer 
have favorable lung cancer‐specific survival during the first 
5 years after diagnosis, but not afterwards, compared with 
patients with first primary lung cancer. Such association is 
independent of tumor characteristics and cancer treatment. 
Our findings suggest that the disease course of lung‐2 is not 
more aggressive than lung‐1. There is not enough reason opt-
ing for conservative care simply because of history of first 
malignancy. The compromised overall survival of lung‐2 pa-
tients in the longer term suggests the importance of active 
management and surveillance of first malignancy for opti-
mizing overall survival.
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